Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3571 - JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non-Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Clinical Research

Tumour Site


Byoung Chul Cho


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


B.C. Cho1, J. Lee2, J. Han3, E.K. Cho4, E. Haura5, K.H. Lee6, J. Bauml7, R.E. Sanborn8, M. Curtis9, E. Attiyeh9, N. Haddish-Berhane9, K. Bae9, R. Knoblauch9, L. Sherman9, M.V. Lorenzi9, K. Park10

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 2 Department Of Internal Medicine, Seoul National University Bundang Hospital, 13620 - Gyeonggi-do/KR
  • 3 Center For Lung Cancer, National Cancer Center, 10408 - Goyang/KR
  • 4 Department Of Internal Medicine, Gachon University Gil Medical Center, 21565 - Incheon/KR
  • 5 Department Of Thoracic Oncology, H. Lee Moffitt Cancer Center, 33612 - Tampa/US
  • 6 Department Of Internal Medicine, Chungbuk National University Hospital, 28644 - Cheongju/KR
  • 7 Department Of Medicine, Perelman School of Medicine at the University of Pennsylvania, 19104 - Philadelphia/US
  • 8 Earle A. Chiles Research Institute, Providence Cancer Institute, 97213 - Portland/US
  • 9 Clinical Oncology, Janssen Research & Development, Raritan/US
  • 10 Department Of Medicine, Samsung Medical Center, 135-710 - Seoul/KR


Abstract 3571


JNJ-372 has demonstrated activity in EGFR and cMET-driven tumor models. In an ongoing phase 1 study of JNJ-372 in patients (pts) with advanced NSCLC, 1050 mg was identified as a recommended phase 2 dose in dose escalation (Part 1) and is being explored in the dose expansion of pts with EGFR-mutated (mut) NSCLC (Part 2).


Pts were treated with JNJ-372 IV weekly x 4W for cycle 1, then biweekly thereafter. Pharmacokinetic (PK) sampling was taken at multiple time points for all pts in Part 1 and for the first 6 pts in Part 2. Disease evaluations were performed every 8 weeks. Tumors were characterized at baseline through next-generation sequencing of ctDNA and/or tumor tissue.


As of April 13th, 2018, 55 pts received JNJ-372 in Part 1 (n = 30) or Part 2 (n = 25), with 21 pts (38%) continuing therapy. Median age was 63y, 40% were male, 96% were Asian, and median prior systemic therapies was 2. The most frequent (≥15%) adverse events (AEs) were infusion-related reaction (56%), rash/acneiform dermatitis (53%), dyspnea (20%), paronychia (24%), nausea (22%), constipation (18%), stomatitis (18%), decreased appetite (18%), pruritus (16%), fatigue (16%), and peripheral edema (16%). AEs were mostly grade 1-2, with 3 ≥grade 3 treatment-related AEs (myalgia, neutropenia, and peripheral edema, all grade 3). PK was linear and dose proportional at doses ≥350 mg, with faster clearance PK at the 140-mg dose. Of the 30 response-evaluable pts with EGFRmut disease, treated at doses ≥700 mg, there are 8 partial responses (PRs; 4 confirmed PRs). This includes 6 pts with L858R or Exon19del primary mutations, and acquired resistance to first and/or third-generation EGFR tyrosine kinase inhibitors (TKIs), and 2 pts with primary Exon20ins disease. Activity was also observed in 2 pts with EGFRwt disease (squamous cell carcinoma and pleomorphic adenocarcinoma), each with -20% change in sum of largest diameter. The longest duration of treatment was 13.6 months.


JNJ-372 is a novel EGFR-cMET bispecific antibody with a manageable safety profile consistent with EGFR and cMET inhibition. Preliminary evidence suggests JNJ-372 can have activity in EGFR-driven NSCLC, including pts resistant to EGFR TKIs.

Clinical trial identification

NCT02609776 First posted: November 20, 2015.

Legal entity responsible for the study

Janssen Research & Development.


Janssen Research & Development.

Editorial Acknowledgement

Writing support was provided by Tracy T. Cao, PhD of Janssen Global Services, LLC. and funded by Janssen Global Services, LLC.


B.C. Cho: Research funding: Janssen, Novartis, AstraZeneca, Yuhan, Champions Oncology, Abbvie, Dong-A ST, Ono, MOGAM; Honoraria: AstraZeneca, Novartis, MSD, Ono, Roche; Consulting or Advisory role: Janssen, AstraZeneca, Novartis, MSD, Roche, Yuhan; Speakers’ bureau: Novartis J-Y. Han: Research funding: Roche. E. Haura: Research funding: Lilly, Novartis, Boehringer Ingelheim, Janssen, Ignyta, Forma Therapeutics; Consulting or Advisory role: Janssen; Patent: Patent pending on PLA technology related to kinase inhibitor sensitivity biomarkers; Travel/Accommodations: Bristol-Myers Squibb, Roche. J. Bauml: Research funding: Merck, Novartis, Carevive Systems, Janssen, Bayer; Consulting or Advisory Role: Clovis, Bristol-Myers Squibb, Celgene, Boehringer-Ingelheim, AstraZeneca, Genentech, Guardant Health. R.E. Sanborn: Research funding: Merck (investigator-initiated study), Bristol-Myers Squibb (institutional research support), MedImmune (institutional research support); Honoraria: AstraZeneca; Consulting or Advisory Role: AstraZeneca, Seattle Genetics, Takeda, Genentech, Abbvie, Celldex; Travel/Accommodations: Janssen. M. Curtis, E. Attiyeh, N. Haddish-Berhane, K. Bae, R. Knoblauch, L. Sherman, M.V. Lorenzi: Employment: Janssen Stock: Johnson & Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.